Barbash Israel M, Waksman Ron
Interventional Cardiology, MedStar Washington Hospital Center, 110 Irving Street, NW, Suite 4B-1, Washington, DC 20010, USA.
Cardiovasc Revasc Med. 2013 Jul-Aug;14(4):229-35. doi: 10.1016/j.carrev.2013.02.004.
Despite a wide range of drug treatment for hypertension, resistant hypertension rates remain high. The Symplicity™ Renal Denervation System (Medtronic, Santa Rosa, CA), which creates renal nerve denervation, has shown initial success in lowering blood pressure among patients with resistant hypertension. Given the enormous market for this treatment approach, an estimated two dozen other companies are pursuing technologies with alternative approaches. Despite this fact, very little has been published on preclinical and clinical experience with these new devices. The current review summarizes the most prominent technologies in the pipeline and provides insight into the mechanism of action, preclinical, and clinical experience with these new devices.
尽管针对高血压有多种药物治疗方法,但顽固性高血压的发生率仍然很高。能够实现肾神经去神经支配的Symplicity™肾去神经支配系统(美敦力公司,加利福尼亚州圣罗莎)已在降低顽固性高血压患者的血压方面初显成效。鉴于这种治疗方法的巨大市场,估计还有二十几家公司正在研发采用替代方法的技术。尽管如此,关于这些新设备的临床前和临床经验的报道却很少。本综述总结了正在研发中的最突出技术,并深入探讨了这些新设备的作用机制、临床前及临床经验。